Myeloid cell leukemia-1 dependence in acute myeloid leukemia: a novel approach to patient therapy

Tapan Mahendra Kadia _, Hagop M. Kantarjian and Marina Konopleva

PDF  |  Full Text  |  How to cite

Oncotarget. 2019; 10:1250-1265. https://doi.org/10.18632/oncotarget.26579

Metrics: PDF 1713 views  |   Full Text 2500 views  |   ?  


Tapan Mahendra Kadia1, Hagop M. Kantarjian1 and Marina Konopleva1

1The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Correspondence to:

Tapan Mahendra Kadia, email: [email protected]

Keywords: AML; BCL-2; MCL-1; flavopiridol; alvocidib

Received: November 08, 2018    Accepted: December 16, 2018    Published: February 08, 2019


Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults, affecting approximately 21,000 people annually (nearly 11,000 deaths) in the United States. B-cell lymphoma 2 (BCL-2) family proteins, notably myeloid cell leukemia-1 (MCL-1), have been associated with both the development and persistence of AML. MCL-1 is one of the predominant BCL-2 family members expressed in samples from patients with untreated AML. MCL-1 is a critical cell survival factor for cancer and contributes to chemotherapy resistance by directly affecting cell death pathways. Here, we review the role of MCL-1 in AML and the mechanisms by which the potent cyclin-dependent kinase 9 inhibitor alvocidib, through regulation of MCL-1, may serve as a rational therapeutic approach against the disease.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26579